GV contributed to a round for MIT-founded small molecule cancer drug spinout Kronos Bio, adding to $18m raised by the latter 14 months ago.
Kronos Bio, a US-based small molecule cancer drug spinout of Massachusetts Institute of Technology (MIT), yesterday closed a $105m series A round featuring GV, a corporate venturing arm of internet technology conglomerate Alphabet.
The round was co-led by venture capital firm Vida Ventures and investment firm Omega Funds, with commitments from Nextech, Perceptive Advisors, Invus, Polaris Partners, Kronos president and CEO Norbert Bischofberger and assorted board directors.
Founded in 2017, Kronos Bio hopes to leverage its small molecule…
